Furthermore, our data suggest that mTOR inhibitors can suppress autocrine and paracrine growth stimulation of tumor and lymphatic endothelial cells by impairing VEGF-C/VEGFR-3 axis and release of soluble VEGFR-2. This evidence concerns the gene FLT4 and neoplasm.